Originally published by our sister publication Infectious Disease Special Edition
Just 12 new antibiotics entered the market from 2017 to 2021, according to the World Health Organization.
Unfortunately, there are far too few investigational antibiotics (just 27) under development against pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, considered critical by WHO. Of these 27, only six are considered “innovative” enough to be capable of overcoming antibiotic